SUBSCRIBE
SUBSCRIBE
News   Business

Johnson & Johnson Signs Potential $500 Million Drug Deal with Astex Therapeutics

June 9, 2008 | 
1 min read
LONDON, June 9 (Reuters) - Britain's Astex Therapeutics has signed a cancer drug research deal with Johnson & Johnson potentially worth more than $500 million in milestone payments, it said on Monday.
Alliances Mergers & acquisitions Europe
Johnson & Johnson Family of Companies
MORE ON THIS TOPIC
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Mythic Cuts Staff While Sharpening Focus on Lead Candidate
October 6, 2025
 · 
215 min read
 · 
BioSpace Editorial Staff
Facade of AstraZeneca's office in Shanghai, China
Artificial intelligence
AstraZeneca Makes Another AI Deal With $555M Algen Alliance
October 6, 2025
 · 
2 min read
 · 
Tristan Manalac
Two human hands with a gesture of a handshake agreement and dollar banknotes with dollar signs on a colored background. Concept of business contract or agreement. Collage art
Mergers & acquisitions
Chiesi, Arbor Weave $2.1B Rare Disease Pact
October 6, 2025
 · 
1 min read
 · 
Tristan Manalac
Group of blue paper boats following on red on yellow background, mass manipulation
Mergers & acquisitions
How Akero’s MASH Success Drove Roche’s $3.5B Takeout of 89bio
October 2, 2025
 · 
3 min read
 · 
Annalee Armstrong